Regained functioning, i.e., a GFS score >=61. Partial ECR did not meet these criteria.

Results: At one year follow-up, 47% met the criteria for no-ECR, 29% the criteria for ECR and 24% the criteria for partial ECR. Baseline predictors of the no-ECR group corresponded to previously identified predictors of long-term TR. Only 35 (17%) participants met the full criteria for TR at this point. Of the 97 in the no-ECR group, 18 (19%) were in an ongoing trial (p<0.001 vs ECR/partial ECR) and 21 (22%) were using the same medication over the whole follow-up year (p =0.008 vs ECR /partial ECR) despite lack of significant clinical effect.

Conclusions: We show that the mostly used consensus definition of TR identifies only a proportion of FEP patients without sufficient clinical and functional improvement at one year follow-up. The main reason for not meeting the criteria is a lack of two adequate antipsychotic trials at this point of time. However, only half of these were in an ongoing trial despite recommendations in clinical guidelines.

Disclosure of Interest: None Declared

EPP0661

Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Findings from the EUGEI study

L. Fusar-Poli 1, E.-G.-W. 6. Investigators 3, G. Investigators 2, J. van Os 2,3,4, B. P. Rutten 3 and S. Guloksuz 2,5

1Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 2Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht; 3UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands; 4Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom and 5Department of Psychiatry, Yale University School of Medicine, New Haven, United States

*Corresponding author.
doi: 10.1192/j.eurpsy.2023.957

Introduction: Schizophrenia spectrum disorders (SSD) are frequently associated with disturbances in both neurocognition and social cognition. The pathoetiology of SSD derives from a complex interaction between genes and environment. Exposome score for schizophrenia (ES-SCZ) is a cumulative environmental exposure score for schizophrenia which have shown potential utility in risk stratification and outcome prediction.

Objectives: To investigate whether ES-SCZ is associated with cognition in patients with SSD, unaffected siblings, and healthy controls.

Methods: The present cross-sectional study included 1141 patients with SSD, 1332 unaffected siblings, and 1495 healthy controls, recruited in the Netherlands, Spain, Serbia, and Turkey. The Wechsler Adult Intelligence Scale (WAIS) was used to evaluate neurocognition, while the Degraded Facial Emotion Recognition (DFAR) task was used to assess social cognition. ES-SCZ was calculated based on our previously validated method. Associations between ES-SCZ and cognitive domains were analyzed by applying regression models in each group (patients, siblings, and controls), adjusted by age, sex, and country.

Results: According to our preliminary analyses, no significant associations were found between ES-SCZ and cognition in patients with SSD. ES-SCZ was negatively associated with WAIS in unaffected siblings (β=-0.40, p=0.03) and controls (β=-0.63, p=0.004) and positively associated with DFAR in siblings (β=0.83, p=0.004). No significant association between ES-SCZ and DFAR was found in healthy controls.

Conclusions: Our findings show that neurocognition and social cognition are oppositely associated with ES-SCZ. Longitudinal studies may clarify whether there is a cause-effect relationship between ES-SCZ and cognition. Further research should investigate whether ES-SCZ interacts with molecular genetic risk for schizophrenia to improve clinical characterization and outcome prediction in people with SSD.

Disclosure of Interest: None Declared

EPP0662

Night-time/daytime Protein S100B serum levels in paranoid schizophrenic patients

E. Diaz-Mesa 1,2, A. Morera-Fumero 3, L. Torres-Tejera 1,4, A. Crisostomo-Siverio 1, P. Abreu-Gonzalez 3, R. Zuñiga-Costa 1, S. Yelmo-Cruz 1, R. Cejas-Mendez 2,3, C. Rodriguez-Jimenez 4, L. Fernandez-Lopez 1, M. Henry-Benitez 2

1Service of Psychiatry, University Hospital of the Canaries; 2University of La Laguna Department of Internal Medicine Dermatology and Psychiatry, School of Medicine; 3Department of Physiology, University of La Laguna and 4Service of Farmacology, University Hospital of the Canaries, La Laguna, Spain

*Corresponding author.
doi: 10.1192/j.eurpsy.2023.958

Introduction: S100B is a calcium-binding astrocyte-specific cytokine, that is considered a biomarker of neurodegeneration; which may be involved in the imbalance of the inflammatory response observed in several brain disorders, including major depression and schizophrenia. Two meta-analyses have reported higher serum levels of S100B in patients with schizophrenia respect to healthy controls.

Different studies have described circadian and seasonal variations of biological variables, such as melatonin or cortisol. It has been reported that there is not circadian rhythm of S100B blood levels in healthy subjects. However, it is not known whether there are circadian oscillations in S100B blood concentrations in patients with schizophrenia.

Objectives: The aim of this study is to describe S100B serum levels in patients with schizophrenia and to analyse whether they follow a circadian rhythm.

Methods: Our sample consists in 47 patients in acute phase and stabilized status. Blood samples were collected at 12:00 and 00:00 hours by venipuncture. Serum levels of Protein S100B were measured three times: at admission, discharge and three months after discharge. Protein S100B was measured by means of ELISA (Enzyme-linked immunosorbent assay) techniques.
Results:

<table>
<thead>
<tr>
<th></th>
<th>12:00</th>
<th>24:00</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admision</td>
<td>132,95±199,27</td>
<td>85,85±121,44</td>
<td>0,004</td>
</tr>
<tr>
<td>Discharge</td>
<td>73,65±71,744</td>
<td>75,80±123,628</td>
<td>0,070</td>
</tr>
<tr>
<td>Control</td>
<td>43,49±34,60</td>
<td>40,14±23,08</td>
<td>0,47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>P global</th>
<th>P admission vs. discharge</th>
<th>P admission vs. control</th>
<th>P discharge vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0,97</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There is a significant difference between 12:00 and 24:00 at admission for the Protein S100B. However, these differences did not occur at discharge and at three months after discharge. It can be interpreted as there is a circadian rhythm of Protein S100B when the patient has not yet had a psychotic relapse, and it disappears at discharge and when the psychopathology is stable.

Conclusions: With respect to our results, we can hypothesize that clozapine patients in acute relapse present circadian S100B rhythm that is not present when the patients are clinically stable. Furthermore, the decrease of serum protein S100B levels at discharge is indicative of a reduction of the cerebral inflammation, thus it can be a biomarker of cerebral inflammation and this reduction can be the effect of the treatment. Finally, its circadianity could be a guide of this process and clinical improvement.

Disclosure of Interest: None Declared

EPP0663

Analysis of the predictive potential of good clinical response of plasma levels of clozapine in patients with resistant schizophrenia in an area of southern Spain

L. I. Muñoz-Manchado¹, F. González-Saiz¹, J. I. Pérez-Revuelta¹, N. Laherrán-Cantera¹ and R. J. Pardo-Velasco²

¹Mental Health Unit, UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera. Fundación Biomédica de Cádiz. and ²Mental Health Unit, Student of the university master’s degree in initiation to mental health research, University of Cadiz, Jerez de la Frontera, Cádiz, Spain

Introduction: Resistant schizophrenia is a schizophrenia subtype characterized by a non-ability to respond to an appropriate antipsychotic treatment in dosage and duration by the patients. These patients show a lower prognostic and symptomatic profile. The unique drug which has shown efficacy for resistant schizophrenia treatment is clozapine, which is effective in suicide and aggressive behaviour prevention too. Whereas clozapine has numerous and serious adverse effects such as agranulocytosis risk. Because of this, and for guaranteeing an accurate diagnosis of resistant schizophrenia, distinguishing this from pseudo-resistance due to a poor tracing of schizophrenia, clozapine’s plasmatic levels monitoring is recommended in Spain by many clinical practise-guidelines.

Objectives: This study has the objective of determining if altered clozapine’s plasmatic levels have predictive potential of therapeutic response and answering what clinical and sociodemographic variables are associated to these abnormal plasmatic levels.

Methods: In this work, a cross-sectional observational study was carried out in which clinical and sociodemographic data obtained by the Mental Health Unit of the Jerez de la Frontera University Hospital were collected within the research project entitled: “Role of social cognition as a factor psychosocial functioning of the schizophrenic patient” (ECOFUN), of all the participating patients (in total the sample was 141 patients, of which 40 are in treatment with clozapine). Results: The sample of patients has a mean age of 44 years and medium-high educational levels. The vast majority are men and do not currently consume substances of abuse, and when this consumption occurs, tobacco and alcohol are the most consumed substances. Their total scores on the PANSS and Markova Barrios scales are generally very disparate, but with average values of 55 and 16. It has been obtained as results that there is no significant statistical correlation between the plasma levels of clozapine and the values of the PANSS scale and its subscales in the patients. On the other hand, patients treated with clozapine would present clinical and sociodemographic characteristics practically identical to those of patients treated with other antipsychotics, especially their values on the PANSS scale. In addition, plasma levels of clozapine are correlated, although not significantly, with an improvement in the positive symptomatology of schizophrenia.

Conclusions: As a conclusion, unusually higher values of clozapine are correlated significantly with lower values in positive symptomatology in schizophrenia, but plasmatic levels are not correlated significantly with values of PANSS scale.

Disclosure of Interest: None Declared

EPP0664

Disorganization in first episode schizophrenia: psychopathological findings and treatment response from a 2-year Italian follow-up research in a real-world setting

L. Pelizza*, E. Leuci and E. Quattrone

Department of Mental Health, AUSL di Parma, Parma, Italy

*Corresponding author.


Introduction: Disorganization is a core dimension of schizophrenia, yet it is relatively under-investigated compared to positive and negative ones, especially at the illness onset. Indeed, most of the empirical studies investigating the disorganized domain included patients with prolonged schizophrenia.

Objectives: Thus, the aims of this research were (1) to monitor the longitudinal stability of disorganized symptoms in young patients with First Episode Schizophrenia (FES) along a 2-year follow-up period, and (2) to examine any significant association of disorganization with functioning, psychopathology and the specific treatment components of an “Early Intervention in Psychosis” (EIP) program across the 2 years of follow-up.

Methods: At baseline, 159 FES individuals (aged 12–35 years) completed the Positive And Negative Syndrome Scale (PANSS)